SEBIVO(R) (telbivudine) Recommended For Approval In European Union As A New Treatment For Patients With Chronic Hepatitis B

Sat, 24 Feb 2007 02:00 PM EST

... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) today announced the adoption of a positive opinion by the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP), recommending granting of marketing authorization of SEBIVO(R) (telbivudine), a once-a-day tablet taken with or without food, for the treatment of chronic hepatitis B infection in adult patients. [click link for full article] ...